1999
DOI: 10.1016/s0924-977x(99)80468-4
|View full text |Cite
|
Sign up to set email alerts
|

Clinical efficacy of exelon in patients with Alzheimer's disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
7
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(7 citation statements)
references
References 0 publications
0
7
0
Order By: Relevance
“…More recently, the clinical efficacy of Cerebrolysin in AD dementia has been evaluated in seven randomized, double-blind, controlled clinical trials (RCTs), [212][213][214][215][216][217][218] in five other trials, [219][220][221][222][223] and in one clinical series. 224 Longterm effects of Cerebrolysin on cognitive performance and the rate of AD conversion in MCI subjects were F I G U R E 1 Multitarget neurotrophic mode of action of Cerebrolysin.…”
Section: Use Of Cerebrolysin In Ad Therapy and Preventionmentioning
confidence: 99%
See 4 more Smart Citations
“…More recently, the clinical efficacy of Cerebrolysin in AD dementia has been evaluated in seven randomized, double-blind, controlled clinical trials (RCTs), [212][213][214][215][216][217][218] in five other trials, [219][220][221][222][223] and in one clinical series. 224 Longterm effects of Cerebrolysin on cognitive performance and the rate of AD conversion in MCI subjects were F I G U R E 1 Multitarget neurotrophic mode of action of Cerebrolysin.…”
Section: Use Of Cerebrolysin In Ad Therapy and Preventionmentioning
confidence: 99%
“…Thick line illustrate treatment differences (TD) with respect to placebo for Cerebrolysin 10 and 30 ml. Data of four clinical trials using two treatment courses were selected to calculate average ADAS-cog scores of change from baseline in patients treated with placebo, 215,217 10-217,218 or 30-ml 215,217,222 Cerebrolysin. Three trials used the same design: 40 iv infusions on Weeks 1-4 and 13-16, and evaluations at 4, 16, and 28 weeks.…”
Section: Clinical Efficacy Of Cerebrolysin In Ad Dementia: Placebo-control Studiesmentioning
confidence: 99%
See 3 more Smart Citations